Industry News (Therapy)

Treatment IND Filed for Gliadel To Treat Malignant Glioma

Published in Cancer Weekly, October 16th, 1995

Guilford Pharmaceuticals Inc., Baltimore, Maryland, announced that it has submitted to the U.S. Food and Drug Administration (FDA) a treatment Investigational New Drug (IND) application for Gliadel.

Gliadel is a biodegradable polymer implant which is being developed by Guilford for the treatment of malignant glioma, the most common and rapidly fatal type of brain cancer. Gliadel polymer implants are small white wafers which are left in the surgical cavities created when a brain tumor is removed. As the wafer slowly erodes in the brain, it releases the cancer chemotherapeutic drug carmustine (BCNU) directly to the tumor site in high concentrations over an extended...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry